Similarly, the activation of liver AMPK, a well-known regulator of lipid metabolism and a direct upstream regulator of CPT1A, inhibited the accumulation of lipids in mouse liver and the development of nonalcoholic fatty liver disease (NAFLD) [20,21]. This evidence concerns the gene CPT1A and metabolic dysfunction-associated steatotic liver disease.